Jul 23, 2023, 16:19
The first oral SERD gets closer to Europe – Paolo Tarantino
Positive CHMP opinion on the marketing authorization of elacestrant for patients with HR+/HER2- MBC with detectable ESR1 mutations. The first oral SERD gets closer to Europe.
For details: Click here
Source: Paolo Tarantino/Twitter
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 28, 2024, 17:52
Sep 28, 2024, 17:41
Sep 28, 2024, 16:29
Sep 28, 2024, 16:14
Sep 28, 2024, 16:13